Related Experiment Video

Updated: Aug 8, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression

Y S Cho-Chung1

  • 1Cellular Biochemistry Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA.

Antisense & Nucleic Acid Drug Development
|January 1, 1996
PubMed

Insights

Targeting RI alpha, a subunit of cAMP-dependent protein kinase type I, with antisense oligodeoxynucleotides inhibits cancer cell growth. This approach effectively restrains neoplastic growth in vivo with infrequent dosing.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • RI alpha subunit of cAMP-dependent protein kinase type I is overexpressed in various human cancers.
  • This overexpression correlates with cancer cell proliferation and transformation.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting RI alpha gene expression in cancer.
  • To evaluate the efficacy of RI alpha antisense oligodeoxynucleotides in controlling tumor growth.

Main Methods:

  • Sequence-specific inhibition of RI alpha gene expression using antisense oligodeoxynucleotides.
  • In vitro studies on human cancer cell lines (leukemia, epithelial origin).
  • In vivo studies involving single-injection antisense treatment in tumor models.

Main Results:

  • Antisense inhibition of RI alpha induced differentiation in leukemia cells and growth arrest in epithelial cancer cells.
  • In vivo treatment reduced RI alpha expression and inhibited tumor growth.
  • Tumor cells treated with antisense exhibited reduced protein kinase type I levels, mimicking untransformed cells.

Conclusions:

  • RI alpha antisense oligodeoxynucleotides represent a promising strategy for cancer therapy.
  • Targeting RI alpha gene expression can effectively restrain neoplastic growth in vivo.
  • The biochemical changes induced by RI alpha antisense provide a mechanism for growth control with infrequent dosing.

More Related Videos

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...